The Blind Claim: The Three Hidden Failure Points Where Your Enterprise Value Is Actually Decided

When you cross the $1M EBITDA threshold, your P&L is no longer a financial document. It is a claim that will eventually be algorithmically audited.

I spent years on the side that runs these audits. I helped build the operational playbook at a DSO that scaled from 80 to 200+ locations, while simultaneously preparing itself to be looked at through the institutional lens. I have forensically evaluated over 500 practices using the exact lens buyers deploy.

Retail brokers sell a multiple. Institutional buyers underwrite the clinical data beneath it. If you are going to market, these are the three hidden failure points where your enterprise value will actually be decided.

The Clinical Scrub (Not the CPA Haircut)

Sellers expect buyers to normalize owner compensation and challenge add-backs. What they don’t expect is a forensic extraction of their Practice Management Software.

If you claim $1.5M in EBITDA, but a buy-side Quality of Earnings (QoE) team finds undocumented D4341 anomalies, unverified production, and write-off latency in your database, your number shrinks. A $300K clinical haircut at a 7× multiple wipes $2.1 million off your valuation in a spreadsheet you never saw, defended by no one.

And the scrub goes deeper than production. Your CDT utilization gets benchmarked against payer-standard norms. This means buildup frequency against crowns, SRP against perio charting, the billing patterns that read as inflation. Then the ledger side: patient credits aging across three years, refund patterns, bad debt quietly written down. Every one of those data points lives in your PMS. None of them appear on any single default report it generates, and no PMS ships with an industry benchmark to compare against. The software you run your practice on cannot show you your practice the way a buyer will see it.

Understand what is actually being bought. Your trailing twelve months is the baseline — that’s the asset. Everything before it is the inference engine: the buyer reads your billing history the way an underwriter reads a driving record, pricing the probability that the next twelve months look like the claim. A pattern from three years ago discounts the year ahead.

The remedy is unglamorous and decisive: clinical notes that reconcile what was billed months ago. When the documentation in the chart supports the code on the ledger — line after line, year after year — the anomaly list comes back short, and the haircut has nothing to grab.

Key-Person Risk Is Priced in Terms, Not Just Multiples

Clinical dependency rarely kills a deal, but it completely rewrites the mechanics of your payout.

Buyers separate a platform from a solo-job by auditing procedural concentration. If your data proves the majority of high-margin production is tied strictly to your NPI number, the multiple might survive, but the cash at close will drop. You will be handed a longer earnout and a massive holdback, making your money contingent on a version of the practice that disappears the day you stop drilling.

The clinical dependency audit starts on four questions, all answerable from your database: where do new patients come from, who sees the exams, who presents the treatment, and who completes it. If you are the only answer to any one of those, or the disproportionately responsible one, that is a clinical dependency. It gets priced into the package, and then resolved by the buyer after the transaction, on their terms, at your expense.

It doesn’t stop there. Are there procedures only you perform, ones that walk out the door with you, or get referred out of the practice the day after close? Is there a succession plan in the building, or does the org chart end at your chair? From a PE buyer’s perspective, every one of those is not a question. It is a risk carrying a price.

What does good look like? An owner engineering himself toward optional, both clinically and operationally. Associates seeing a growing share of the exams and presenting their own treatment plans. High-skill procedures completed by multiple providers or transitioned over a defined runway. New patients arriving through the practice’s brand and referral architecture, not the owner’s name and brand. You don’t have to be absent. You have to be replaceable on paper.

The real bottom line question, “how does this practice run without you?” dictates the terms of you leaving.

Growth Requires Receipts, Not Hunches

A growth story without database documentation is priced at zero.

From a recent forensic engagement: A multi-location group claimed a massive growth trajectory based on 5,294 new patient visits in twelve months. But when we rebuilt the clinical retention data, only 1,412 of those patients (18.7%, against a 45% benchmark) had a future appointment on the books. Half the flow came from a paid aggregator with terrible retention.

That is not a growth engine; it is a treadmill. One cohort’s retention gap, compounded forward, priced out at $5.26M in foregone revenue over five years. The buyer’s model will not credit the growth; it prices the leak — the same mechanism that makes Toxic Top-Line revenue worth less than it collects.

Now understand what happens to a database like that in diligence. The buyer doesn’t read your numbers in isolation, they are benchmarked against every practice in their organization. A new-patient leak at that rate jumps off the page, because no operator on their side would pour marketing dollars into a bucket before fixing the holes. And they keep reading. They see the owner running a case-acceptance rate 15 points higher than every associate, while personally seeing 70% of the new patients. In one query, key-person risk stops being a diligence question and becomes a proven fact of the database. They will price the remediation into the package through one tool or another: the price, the earnout, the holdback.

This is the asymmetry that decides deals. The buyer has rebuilt this exact story from hundreds of databases. You have seen one and never through their lens. Show up without your own facts and your own narrative, and their story becomes the story. You’re not negotiating at that point. You’re accepting.

The Unseen Earnout Clause

An earnout is not a financial target. It is a contractual agreement to hit specific performance metrics while someone else controls your staffing, your fee schedules, and your overhead allocation for the next three to five years. If you do not legally define how your EBITDA is measured post-close, you have handed the steering wheel to the buyer while keeping the liability yourself.

Here is what that looks like in dollars. Say you defended your number and it held: $1.5M of EBITDA at 7×, a $10.5M deal, with 20% structured as an earnout. That’s $2.1M, payable if the practice holds its EBITDA over three years.

On the buyer’s paper, “EBITDA” is left undefined. Post-close, the platform allocates its overhead down to your practice: a 5% management fee, centralized billing, recruiting, IT. On $5M of collections, that is $250K of new “expense” the practice never carried before. Your operation didn’t change. Your measured EBITDA fell to $1.25M anyway. Target missed. Earnout: $0. Nothing was mismanaged, and nothing was breached. The definition did all of it.

The seller-structured version costs nothing but negotiation: EBITDA measured on the same basis as the closing model. Corporate allocations excluded, or capped at the diligence assumption. Monthly reporting with audit rights. A pro-rata payout instead of a cliff. And covenants that adjust the target if the buyer cuts the levers that produce it such as, staffing, marketing, and/or fee schedules.

Same practice. Same performance. $2.1M instead of $0. The definition is the deal.

The Move

Every one of these threats is quantifiable before you go to market. The QoE haircut, the clinical dependency discount, and the undefined earnout metric are conceded by sellers who fail to run the same diligence on their own asset.

The buyer’s QoE team will rebuild your number regardless. The only question is whether you have defensible data, or a blind claim.